Create Alert
Watchlist

Zydus Lifesciences

639.70
+2.15 (0.34%) 1D
NSE
1D
1W
1M
1Y
3Y
5Y
All

Performance

Open
641.70
Prev. Close
637.55
Volume
11,35,068
Total traded value
72.61 Cr
Upper Circuit
701.30
Lower Circuit
573.80

Market Depth

Buy order quantity
Sell order quantity
%
%
Loading...
Bid Total
51
Loading...
Ask Total
0

Analyst Estimates

39%
Buy
39%
Hold
36%
Sell
25%
Aggregated by Refinitiv from 28 Analysts

Fundamentals

Market Cap₹64,700Cr
ROE17.03%
P/E Ratio(TTM)23.05
EPS(TTM)27.73
P/B Ratio3.45
Dividend Yield0.94%
Industry P/E32.29
Book Value185.07
Debt to Equity0.01
Face Value1
Understand Fundamentals

Financials

*All values are in Rs. Cr
No Graph Data To Display
Quarterly
Yearly

About Zydus Lifesciences

Zydus Lifesciences Ltd. is an India-based life sciences company. The Company is engaged in the research and development, manufacturing, marketing and selling of finished dosage human formulations, such as generics and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients (APIs); animal healthcare products, and consumer wellness products. Its products include Bilypsa (saroglitizar), Oxemia (desidustat), Ujvira (biosimilar Kadcyla), and Exemptia. It offers Bilypsa drug for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Desidustat is an oral, small molecule hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor, which is used for the treatment of anemia in chronic kidney disease (CKD) patients. It is also developing an oral small molecule ZYIL1, targeted at selectively suppressing inflammation caused by the NLRP3 inflammasome. Its ZyCoV-D is a plasmid deoxyribonucleic acid (DNA) vaccine for COVID-19.;
Parent OrganisationZydus Lifesciences
Founded1995
Managing DirectorDr. Sharvil Patel
NSE SymbolZYDUSLIFE

Shareholding Pattern

Sep '22
Dec '22
Mar '23
Jun '23
Sep '23
Promoters
74.98%
Retail And Others
7.37%
Other Domestic Institutions
6.86%
Mutual Funds
5.94%
Foreign Institutions
4.85%

Similar Stocks

COMPANY
52 WEEK
MARKET PRICE
P/E Ratio
Sun Pharmaceutical Industries
₹1,226.00
(-0.43%)
34.56
Cipla
₹1,211.55
(+0.49%)
28.21
Dr Reddy's Laboratories
₹5,761.85
(+0.22%)
18.83
Mankind Pharma
NA
(0.00%)
49.31
ⓒ 2016-2023 Groww. All rights reserved, Built with in India
MOST POPULAR ON GROWWVERSION - 4.5.1
STOCK MARKET INDICES:  S&P BSE SENSEX |  S&P BSE 100 |  NIFTY 100 |  NIFTY 50 |  NIFTY MIDCAP 100 |  NIFTY BANK |  NIFTY NEXT 50
MUTUAL FUNDS COMPANIES:  GROWWMF |  SBI |  AXIS |  HDFC |  UTI |  NIPPON INDIA |  ICICI PRUDENTIAL |  TATA |  KOTAK MAHINDRA |  DSP |  CANARA ROBECO |  SUNDARAM |  MIRAE ASSET |  BANDHAN |  FRANKLIN TEMPLETON |  PPFAS |  MOTILAL OSWAL |  INVESCO |  EDELWEISS |  ADITYA BIRLA SUN LIFE |  LIC |  HSBC |  NAVI |  QUANTUM |  UNION |  IDBI |  ITI |  MAHINDRA MANULIFE |  360 ONE |  BOI |  TAURUS |  JM FINANCIAL |  PGIM |  SHRIRAM |  BARODA BNP PARIBAS |  QUANT |  WHITEOAK CAPITAL |  TRUST |  SAMCO |  NJ |  BAJAJ

ABOUT GROWW